



24<sup>th</sup> April 2015

**Educational Materials:**

**Medicines containing valproate: risk of abnormal pregnancy outcomes (Epilim oral range, Epilim Chrono and Epilim IV range)**

Dear Healthcare Professional,

Further to the Direct Healthcare Professional Communication letter in December 2014, informing you of important new information and strengthened warnings related to safety of medicines containing valproate (sodium valproate, valproic acid, valproate semisodium and valpromide) following completion of a Europe-wide review, this letter relates to the educational materials which are now being made available.

The educational materials enclosed consist of:

- Valproate Guide for Prescribers
- Valproate Patient Information Booklet
- Valproate Information Form

It is strongly recommended that the Valproate Patient Information form together with the Valproate Patient Booklet is used to ensure that adequate information is provided to patients prior to prescribing medicines containing valproate. Patients or their carers may sign this form and a copy may be retained in their medical records where this is helpful in your clinical practice.

**Company contact point**

Further copies of the educational materials are available on [www.sanofi.ie](http://www.sanofi.ie) or by contacting our medical information department at [IEMedinfo@sanofi.com](mailto:IEMedinfo@sanofi.com) or at telephone number (01) 4035600.

A handwritten signature in cursive script, appearing to read "Liz Bergin", is written over a horizontal line.

Dr. Liz Bergin, 022591

**Medical Director, Sanofi Ireland**